AstraZeneca

Open: 69.94 Close: 69.51 Change: -0.43

Our AI found unexpected things about AstraZeneca Company Inc.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, PLC, share, price, rating, China, receive, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Average price target for AstraZeneca is $79.25, which is 14.01% higher than the current price. HSBC assumed coverage on AstraZeca in a research report on Friday.

Today's News

Enhertu was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. China-based Amoy said the therapy is approved in China to treat patients who have received previous treatments for HER2-low and HER2. AstraZeneca PLC ( LON:AZN ) share price is up 86% in the last 5 years, besting the market decline of around 7.0% (ignoring dividends) During the last half decade, AstraZecas became profitable. Average price target for AstraZeneca is $79.25, which is 14.01% higher than the current price. HSBC assumed coverage on AstraZeca in a research report on Friday. AstraZeneca is the largest foreign drugmaker in China and is doubling down on the world No.2 pharmaceutical market. CanSino Biologics (6185.HK) has agreed to provide contract development and manufacturing services. AstraZeneca PLC (NASDAQ:AZN) has received a consensus rating of “Moderate Buy” from the eight ratings firms that currently cover the stock. StockNews.com initiated coverage on Astra Zeneca with a “strong-buy” rating. Bradley Foster Sargent Inc. trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN Free Report) Bradley Foster. CT trimmed its. position in. shares by 39.9% during the first quarter. AstraZeneca is in the Health Care sector and Pharmaceuticals industry. Q3 earnings are confirmed for Thursday, November 9, 2023. There is no upcoming split. Astrazeneca PLC ADR underperforms Tuesday when compared to competitors - marketwatch.com. AstraZeneca PARC ADR slipped 1.88% to $69.51 Tuesday, on what proved to be an all-around grim trading session. AstraZeneca PLC has 1,550m shares in circulation. Astrazenecas recently acquired Alexion in 2020, worth a staggering $40 billion.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, PLC, share, price, rating, China, receive, and the most common words in the summary are: astrazeneca, stock, news, market, plc, company, price, . One of the sentences in the summary was: Average price target for AstraZeneca is $79.25, which is 14.01% higher than the current price. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #stock #news #market #plc #company #price.